<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B936D768-A528-4ABB-A6FA-D5F91D6FD0F4"><gtr:id>B936D768-A528-4ABB-A6FA-D5F91D6FD0F4</gtr:id><gtr:name>Defence Science &amp; Technology Laboratory (DSTL)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/017349DC-94C2-4AB9-AAD6-7E6813B6DC64"><gtr:id>017349DC-94C2-4AB9-AAD6-7E6813B6DC64</gtr:id><gtr:name>PaxVax, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C33876E8-7958-41F0-87A6-095798CF94F9"><gtr:id>C33876E8-7958-41F0-87A6-095798CF94F9</gtr:id><gtr:name>Academy of Sciences of the Czech Republic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60F248FE-C8E5-4717-901F-B0303E223FF9"><gtr:id>60F248FE-C8E5-4717-901F-B0303E223FF9</gtr:id><gtr:name>Huntingdon Life Sciences</gtr:name><gtr:address><gtr:line1>Huntingdon Life Sciences</gtr:line1><gtr:line2>Woolley Road</gtr:line2><gtr:line3>Alconbury</gtr:line3><gtr:postCode>PE28 4HS</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3348FD29-79EB-47C2-9639-489D9C4E5DEE"><gtr:id>3348FD29-79EB-47C2-9639-489D9C4E5DEE</gtr:id><gtr:name>Los Alamos National Laboratory</gtr:name><gtr:address><gtr:line1>Los Alamos National Laboratory</gtr:line1><gtr:line2>PO Box 1663</gtr:line2><gtr:line3>Los Alamos</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9ED220E4-E93E-4738-ACD1-D5B2B708EBBB"><gtr:id>9ED220E4-E93E-4738-ACD1-D5B2B708EBBB</gtr:id><gtr:name>Aeras</gtr:name><gtr:address><gtr:line1>1405 Research Blvd</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/743B0403-114A-4062-A04B-26B6E57DE502"><gtr:id>743B0403-114A-4062-A04B-26B6E57DE502</gtr:id><gtr:name>Columbia University</gtr:name><gtr:address><gtr:line1>Columbia University</gtr:line1><gtr:line2>2960 Broadway</gtr:line2><gtr:line4>New York</gtr:line4><gtr:line5>NY 10027-6902</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DFE6B693-9C12-4961-8B35-A4F7346A202A"><gtr:id>DFE6B693-9C12-4961-8B35-A4F7346A202A</gtr:id><gtr:name>Recipharm</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F0218A50-2D74-431E-9B66-7B583688A24A"><gtr:id>F0218A50-2D74-431E-9B66-7B583688A24A</gtr:id><gtr:name>Kumamoto University</gtr:name><gtr:address><gtr:line1>Kumamoto University</gtr:line1><gtr:line2>Honjo 1-1-1</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70713789-B41C-4730-A26D-B92DD613858D"><gtr:id>70713789-B41C-4730-A26D-B92DD613858D</gtr:id><gtr:name>IDT Biologika GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B3793A3A-8D07-453D-9C33-671ECAF26040"><gtr:id>B3793A3A-8D07-453D-9C33-671ECAF26040</gtr:id><gtr:name>Commonwealth Scientific and Industrial Research Organisation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B936D768-A528-4ABB-A6FA-D5F91D6FD0F4"><gtr:id>B936D768-A528-4ABB-A6FA-D5F91D6FD0F4</gtr:id><gtr:name>Defence Science &amp; Technology Laboratory (DSTL)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/017349DC-94C2-4AB9-AAD6-7E6813B6DC64"><gtr:id>017349DC-94C2-4AB9-AAD6-7E6813B6DC64</gtr:id><gtr:name>PaxVax, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C33876E8-7958-41F0-87A6-095798CF94F9"><gtr:id>C33876E8-7958-41F0-87A6-095798CF94F9</gtr:id><gtr:name>Academy of Sciences of the Czech Republic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60F248FE-C8E5-4717-901F-B0303E223FF9"><gtr:id>60F248FE-C8E5-4717-901F-B0303E223FF9</gtr:id><gtr:name>Huntingdon Life Sciences</gtr:name><gtr:address><gtr:line1>Huntingdon Life Sciences</gtr:line1><gtr:line2>Woolley Road</gtr:line2><gtr:line3>Alconbury</gtr:line3><gtr:postCode>PE28 4HS</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3348FD29-79EB-47C2-9639-489D9C4E5DEE"><gtr:id>3348FD29-79EB-47C2-9639-489D9C4E5DEE</gtr:id><gtr:name>Los Alamos National Laboratory</gtr:name><gtr:address><gtr:line1>Los Alamos National Laboratory</gtr:line1><gtr:line2>PO Box 1663</gtr:line2><gtr:line3>Los Alamos</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9ED220E4-E93E-4738-ACD1-D5B2B708EBBB"><gtr:id>9ED220E4-E93E-4738-ACD1-D5B2B708EBBB</gtr:id><gtr:name>Aeras</gtr:name><gtr:address><gtr:line1>1405 Research Blvd</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/743B0403-114A-4062-A04B-26B6E57DE502"><gtr:id>743B0403-114A-4062-A04B-26B6E57DE502</gtr:id><gtr:name>Columbia University</gtr:name><gtr:address><gtr:line1>Columbia University</gtr:line1><gtr:line2>2960 Broadway</gtr:line2><gtr:line4>New York</gtr:line4><gtr:line5>NY 10027-6902</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DFE6B693-9C12-4961-8B35-A4F7346A202A"><gtr:id>DFE6B693-9C12-4961-8B35-A4F7346A202A</gtr:id><gtr:name>Recipharm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F0218A50-2D74-431E-9B66-7B583688A24A"><gtr:id>F0218A50-2D74-431E-9B66-7B583688A24A</gtr:id><gtr:name>Kumamoto University</gtr:name><gtr:address><gtr:line1>Kumamoto University</gtr:line1><gtr:line2>Honjo 1-1-1</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70713789-B41C-4730-A26D-B92DD613858D"><gtr:id>70713789-B41C-4730-A26D-B92DD613858D</gtr:id><gtr:name>IDT Biologika GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B3793A3A-8D07-453D-9C33-671ECAF26040"><gtr:id>B3793A3A-8D07-453D-9C33-671ECAF26040</gtr:id><gtr:name>Commonwealth Scientific and Industrial Research Organisation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8B063DF8-CBFF-4B1C-BE0C-60F2F7CF71D8"><gtr:id>8B063DF8-CBFF-4B1C-BE0C-60F2F7CF71D8</gtr:id><gtr:firstName>Tomas</gtr:firstName><gtr:surname>Hanke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137884179"><gtr:id>7F2ACE6B-E64E-4E85-BD22-7D25C238BF3B</gtr:id><gtr:title>Development of a vaccine against HIV and AIDS</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137884179</gtr:grantReference><gtr:abstractText>a) nature of research - our work aims to develop a protective vaccine against the HIV virus, the causative agent of AIDS; new candidate vaccines/approaches are tested first in animal models and then in human volunteers in UK, Europe and Africa.||b) prospective outcomes - the development of an new vaccine strategy for controlling HIV infection||c) health benefits - potential reduction in the number of HIV infections in developed and developing countries with the aim to eventual control HIV infection and the global AIDS epidemic</gtr:abstractText><gtr:technicalSummary>This project aims to develop a vaccine inducing T cell responses that can on its own or in combination with an antibody-inducing vaccine benefit vaccinees by either preventing HIV-1 infection or improving virus control after infection, and therefore delaying development of AIDS and decreasing transmission to other people.||To accelerate our progress, we run mutually complementing studies in mice, non-human primates (NHP) and humans. We were the first to use a heterologous DNA prime and recombinant modified vaccinia virus Ankara (rMVA) boost regimen delivering a common immunogen derived from an central African HIV-1 strain. In humans (collaboration with Professor Andrew McMichael and Dr Lucy Dorrell), rMVA delivered a consistent and strong boost, while DNA primed consistently, but weakly HIV-1-specific T cell responses.||We explore other vaccine vectors acceptable for use in humans. Most recently, we are developing a recombinant mycobacteria BCG, which is used at birth as a TB vaccine in 80% infants born in Africa, as a vaccine platform for prevention of mother-to-child transmission of HIV-1 through breastfeeding.||We also develop novel HIV-1-derived protein immunogens delivered by the above vaccine vectors. Our latest immunogen is based on conserved regions of the HIV-1 proteome and thus targets all the HIV-1 variants in the target population rather than just the one predominant HIV-1 strain as we did in the past and indeed most other current vaccines under development do.||Experimental design - comparative immunogenicity in animal models, randomised controlled trials in humans||a) tissues, cells, animals used - mice, primates, human blood samples||b) techniques/approaches - heterologous prime-boost combinations of various vaccine vectors and modalities including DNA, MVA, SFV, BCG, human and animal adenoviruses and protein-based delivering a common HIV-1 derived immunogen||c) measurements/outcomes - frequency, functionality, longevity and anatomical distribution of vaccine-induced HIV-1-specific T cells</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2137129</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Huntingdon Life Sciences</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GLP pre-clinical toxicology (HIVA)</gtr:description><gtr:id>4854B297-7075-4C4B-8B51-43F57AD53D1D</gtr:id><gtr:impact>GLP pre-clinical toxicology enables us to test novel vaccine concepts in humans and supports an application to MHRA for Clinical Trial Approval 19770697, 19266489, 18812202, 18440674, 17250931, 17170430, 17013989, 16641265, 16176847, 16641264, 17579081, 17257714</gtr:impact><gtr:outcomeId>46C34225FA0-1</gtr:outcomeId><gtr:partnerContribution>GLP pre-clinical toxicology enables us to test novel vaccine concepts in humans</gtr:partnerContribution><gtr:piContribution>HLS carried pre-clinical toxicology in mice to GLP</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Columbia University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Molecular Virology Division Columbia</gtr:department><gtr:description>Murine EcoHIV challenge model</gtr:description><gtr:id>34753A2E-EC5D-4B64-A4C1-A852B6F07141</gtr:id><gtr:impact>Publication 19585509 and manuscript submitted</gtr:impact><gtr:outcomeId>CNbKvGxrhWc-1</gtr:outcomeId><gtr:partnerContribution>Provided an early efficacy test for our vaccines in mice</gtr:partnerContribution><gtr:piContribution>We have constructed a modified version of the EcoHIV virus and use it in preclinical testing of vaccines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Defence Science &amp; Technology Laboratory (DSTL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Vaccine immunogenicity in non-human primate neonates and adults</gtr:description><gtr:id>06937F35-2798-41F1-A0D1-32FBAADB305C</gtr:id><gtr:impact>Immunogenicity of BCG.HIVA401, MVA.HIVA and OAdV.HIVA vaccines was evaluated in non-human neonates and adults 
Publications 20375158 and 20484495</gtr:impact><gtr:outcomeId>90369DD48AD-1</gtr:outcomeId><gtr:partnerContribution>Housing of animals and performance of procedures</gtr:partnerContribution><gtr:piContribution>We disigned the study and Dstl housed the animals and carried out the study procedures</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Development of Semliki Forest Virus replicon vaccines (HIVconsv)</gtr:description><gtr:id>F6A6E02C-87DC-4D49-B9DD-5898117999DB</gtr:id><gtr:impact>Strong boosting of HIV_1 specific immune responses in mice and non-human primates 
Publication 20468055, two publications in preparation
On going NHP experiment on going</gtr:impact><gtr:outcomeId>3491C26D5D5-1</gtr:outcomeId><gtr:partnerContribution>Availabilityt of a novel vaccine modality</gtr:partnerContribution><gtr:piContribution>We have designed and constructed a novel HIV-1 derived immunogen HIVconsv gene and Karolinska inserted this into virus and DNA-based replicon vaccines (VREP.HIVconsv and DREP.HIVconsv)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PaxVax, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of replication-competent Ad4 vector</gtr:description><gtr:id>DB1BFA7E-B883-4D67-9A1D-F007B120B10E</gtr:id><gtr:impact>Replication-competent human adenovirus vector serotype 4 will be constructed with MRC immunogen and evaluated as a candidate vaccine. Contract has been signed.
Two applications to B&amp;amp;MGF CAVD submitted</gtr:impact><gtr:outcomeId>76633C6DB2C-1</gtr:outcomeId><gtr:partnerContribution>Construction of replication competent new HIV-1 vaccine candidate</gtr:partnerContribution><gtr:piContribution>We provide immunogen, PaxVAx constructs the vaccine, we do immunogenicity</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aeras</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Aeras Global TB Vaccine Foundation</gtr:department><gtr:description>Development of rBCG vaccines (HIVA and HIVconsv)</gtr:description><gtr:id>943CBD3A-AFB0-47F1-9245-9565713D1A94</gtr:id><gtr:impact>Documented T cell immunogenicty in mice and primates including primate neonates. 
Publications 17596303, 20484495, 0375158 and two manuscripts in preparation</gtr:impact><gtr:outcomeId>726F1052819-1</gtr:outcomeId><gtr:partnerContribution>Construction of recombinant BCGs</gtr:partnerContribution><gtr:piContribution>Aeras are experts in design and construction of recombinant BCG vaccine. They inserted the hiva and HIVconsv genes into their AREAS-401 modified BCG strain with increased safety and immunogenicity, two different constructs made by AERAS are in immunogenicities studies in Oxford</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Recipharm</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>RecipharmCobra Biologics (formerly Cobra Biomanufacturing)</gtr:department><gtr:description>GMP manufacture of DNA vaccine pTH.HIVA</gtr:description><gtr:id>390EE317-20CC-41FC-885F-F3EACEE46FC1</gtr:id><gtr:impact>GMP products enable us to test novel vaccine concepts in humans 19770697, 19266489, 18812202, 18440674, 17250931, 17170430, 17013989, 16641265, 16176847</gtr:impact><gtr:outcomeId>FFF2F6DC734-1</gtr:outcomeId><gtr:partnerContribution>GMP products enable us to test novel vaccine concepts in humans</gtr:partnerContribution><gtr:piContribution>We designed and constructed an HIV-1-derived immunogene and the expression cassette, and used Cobra's Operator-Repressor Titration system for manufacture of plasmid with any antibiotic-resistance genes</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Development of SLP.HIVconsv vaccine</gtr:description><gtr:id>78E18B6C-34FC-47A6-A5F5-03CD9D840624</gtr:id><gtr:impact>Novel promising vaccine design, which inudced much broader responses than traditional single-open readign-frame genetic vaccines. This has implications for T cell vaccine design in general. Publication 20468055
Grant submitted to B&amp;amp;MGF CAVD
multidisciplinary</gtr:impact><gtr:outcomeId>8C2F2CD7DEC-1</gtr:outcomeId><gtr:partnerContribution>LUMC provided novel technology for vaccine design</gtr:partnerContribution><gtr:piContribution>We have designed a novel HIV-1 derived immunogen HIVconsv and LUMC synthesized the vaccine designed and Synthetic Long Peptides, both site carry immunogenicty studies
NHP challenge experiment using SIVconsv is under way</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>IAVI-replication-competent virus vectors</gtr:description><gtr:id>81830F10-4828-4A3B-A0BF-7E3FE8A6FCD0</gtr:id><gtr:impact>vector are being constructed</gtr:impact><gtr:outcomeId>tPP6GsAZSH2-1</gtr:outcomeId><gtr:partnerContribution>Provision of highly-purified peptides for the immunologicla readout of HIVconsv-specific responses in animals and humans</gtr:partnerContribution><gtr:piContribution>MRC-owned insert HIVconsv is being inserted into IAVI-owned vectors by IAVI for joint preclinical and clinical collaborative studies</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IDT Biologika GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>GMP manufacture of MVA.HIVA</gtr:description><gtr:id>1AAA6013-D34F-48BD-AAD4-4982EDD2DBDA</gtr:id><gtr:impact>GMP products enable us to test novel vaccine concepts in humans 19770697, 19266489, 18812202, 18440674, 17250931, 17170430, 17013989, 16641265, 16176847, 16641264, 17579081, 17257714
Currently, the MVA.HIVA vaccine is in two clinical trials ininfants in Africa funded by EDCTP</gtr:impact><gtr:outcomeId>31336200CD7-1</gtr:outcomeId><gtr:partnerContribution>GMP products enable us to test novel vaccine concepts in humans</gtr:partnerContribution><gtr:piContribution>We hva designed and constructed the vaccine IDT manufactured it to GMP</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kumamoto</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Development of HIVB-B*5101 vaccines</gtr:description><gtr:id>A62BBCB5-48B7-4828-BDE8-5FECF92667F2</gtr:id><gtr:impact>Novel vaccines have been constructed tailor designed for HLA-B*5101+ patients 
Publication 19585509, manuscript in preparation</gtr:impact><gtr:outcomeId>BD595552EB9-1</gtr:outcomeId><gtr:partnerContribution>Designer on a novel immunogen</gtr:partnerContribution><gtr:piContribution>On Kumamotu advice, we have designed and novel immunogen and constructed novel vaccines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Commonwealth Scientific and Industrial Research Organisation</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Biotech Equity Partners</gtr:department><gtr:description>Development of sheep atadenovirus vectored vaccine OAdV.HIVA</gtr:description><gtr:id>B2F6B0CB-46D2-4DCF-B4DB-8A0E3525EECB</gtr:id><gtr:impact>Recombinant sheep atadenovirus vaccine was highly immunogenic in mice and on-human pirmates. Further development will follow. 19853074 and 20375158</gtr:impact><gtr:outcomeId>D6611FB9C13-1</gtr:outcomeId><gtr:partnerContribution>Availability of a novel vaccine vector</gtr:partnerContribution><gtr:piContribution>We designed and constructed the HIVA gene and BEP constructed the OAdV.HIVA vaccine</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of HAdV19a.vectored vaccines</gtr:description><gtr:id>AE2B7A57-3B81-4B5F-969D-E57D5AF49FA8</gtr:id><gtr:impact>Novel vaccine has been constructed and tested in mice</gtr:impact><gtr:outcomeId>AA76370BB3E-1</gtr:outcomeId><gtr:partnerContribution>Novel vaccine vector tested</gtr:partnerContribution><gtr:piContribution>Our HIVA immunogen was inserted into novel adenovirus (by Warwick) and tested for mouse immunogenicty (MRC)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Targeting vaccine-induced T cell to the gut</gtr:description><gtr:id>CA625A2D-2B6D-4588-B1B6-C8C490F9460A</gtr:id><gtr:impact>Improving of vaccine efficacy through targetting or redirecting T cells into the gut, the main site of initial HIV-1 replication
Manuscript in preparation followed by grant application to B&amp;amp;MGF</gtr:impact><gtr:outcomeId>Li1TYtDfpdm-1</gtr:outcomeId><gtr:partnerContribution>Development of organ-homing expertise</gtr:partnerContribution><gtr:piContribution>Demonstrated targeting of vaccine-induced Th1 T cell responses to the gut</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academy of Sciences of the Czech Republic</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:department>Institute of Microbiology</gtr:department><gtr:description>Enhancing T cell induction though B. pertussis toxin targeting</gtr:description><gtr:id>8A8028B9-0DE9-4304-A7EE-078E9AD15D59</gtr:id><gtr:impact>So far, experimental vaccine have been prepared by our Czech Partners and initial</gtr:impact><gtr:outcomeId>oMntwKeS8VL-1</gtr:outcomeId><gtr:piContribution>We provide immunogen HIVconsv sequence, partners construct experimental vaccine, we do pre-clinical immunogenicity evaluation</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Barcelona (UB)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Construction of BCG.HIVA-Pasteur strain</gtr:description><gtr:id>DC4EE79C-1B15-4C2B-BFCC-67B0B251C4C3</gtr:id><gtr:impact>Demonstration of BCG.HIVA immunogenicity and surrogate efficacy. Concept of a dual vaccine platform against TB and HIV-1 conceived Publications 17596303, 20484495, 20468055one manuscript in preparation</gtr:impact><gtr:outcomeId>5B19294B018-1</gtr:outcomeId><gtr:partnerContribution>Construction of BCG.HIVA derived from the Paster strain</gtr:partnerContribution><gtr:piContribution>We provided HIVA gene and conducted immunogenicity in mice, Barcelona constructed the vaccine and contributed to the design of AREAS recombinant BCG.HIVA401</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Los Alamos National Laboratory</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of a conserved mosaic protein as an immunogen</gtr:description><gtr:id>45AB113C-94F0-4F5D-8919-2920E791E67B</gtr:id><gtr:impact>Early days</gtr:impact><gtr:outcomeId>ArZ75UzU9Wd-1</gtr:outcomeId><gtr:partnerContribution>Providing an expertise in designing a vaccine immunogen</gtr:partnerContribution><gtr:piContribution>We describe what immunogen we would like to design and LANL used their computational power to design this immunogen. We then construct it and develop it</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Vaccine in Practice</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A70047C2-842A-4638-9955-9E4F42F9CCBD</gtr:id><gtr:impact>Publication

none noted by us</gtr:impact><gtr:outcomeId>V8hshSkEo5K</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NDM Podcast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B5BF7870-B804-4B71-976A-2A175D587930</gtr:id><gtr:impact>The podcast is available on the Univesity wensite.

Public understading.</gtr:impact><gtr:outcomeId>hZJmEWSkHTB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>News of the Jenner Vaccine Foundation</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0E321850-EA88-4D60-A135-54408D545167</gtr:id><gtr:impact>publication

The articles were noted locally</gtr:impact><gtr:outcomeId>DNXuPkgo6d1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>JPY</gtr:currCode><gtr:currCountryCode>Japan</gtr:currCountryCode><gtr:currLang>ja_JP</gtr:currLang><gtr:description>Japanese Foundation for AIDS Prevention</gtr:description><gtr:fundingOrg>Japanese Foundation for AIDS Prevention (JFAP)</gtr:fundingOrg><gtr:id>C80DD814-ADB4-4E3C-8705-8860801FE272</gtr:id><gtr:outcomeId>392E366C03A0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1290000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Experimental Medicine II</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0701669</gtr:fundingRef><gtr:id>3B239DC9-C8BF-4A3E-8D21-BD410AB86D2D</gtr:id><gtr:outcomeId>9100D63512D0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>EDCTP Strategic Primer</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>SP.2011.41304.002</gtr:fundingRef><gtr:id>66DA28E8-E972-479C-A9DE-06F8298DED3E</gtr:id><gtr:outcomeId>gwCK25hT2kN</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Industrial Studentship</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F6E48680-2959-4727-BDDF-69BB803D71E6</gtr:id><gtr:outcomeId>77E66BDC37F0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>EDCTP Clinical Trial Grants</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>CT.2006.33111.002</gtr:fundingRef><gtr:id>9CEF92FF-9803-44B1-99C7-05A6191CD437</gtr:id><gtr:outcomeId>E5C5550DA3C0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1322832</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001757/1</gtr:fundingRef><gtr:id>0925E295-61FB-4B5F-99DF-98F3AF12D06C</gtr:id><gtr:outcomeId>VGMwJuofEf80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1031751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DCS</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J008605/1</gtr:fundingRef><gtr:id>5D4EF93F-0179-401C-A6F2-7B5CCB6CCC37</gtr:id><gtr:outcomeId>fvdtzuK7343</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Cross-licence between MRCT and Leiden University Medical Center alow a joint development of the synthetic long peptide-HIVconsv technoogy</gtr:description><gtr:grantRef>MC_U137884179</gtr:grantRef><gtr:id>11608E97-9998-4157-B6AF-569E38F0E233</gtr:id><gtr:impact>The crosslincence has been only just singed. It is expected to support a VC invenstment.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>EsFy8ynRgiv</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>SLP.HIVconsv</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>HIV Consv is a DNA construct that comprises the 14 most conserved regions of the HIV-1 genome. It has been inserted into a range of recombinant vaccine formats and has been shown to be highly immunogenic in mice and non-human primates. Phase I clinical trials with the vaccine will begin in 2010.</gtr:description><gtr:grantRef>MC_U137884179</gtr:grantRef><gtr:id>8C82F346-08FA-4E0E-9DD4-4D7FE2156647</gtr:id><gtr:impact>The invention relates to a novel vaccine candidate against HIV infection. The vaccine construct comprises domains from various HIV proteins. The vaccine is shown to induce cellular immune response in mice and non-human primates.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>E3E49789B85</gtr:outcomeId><gtr:patentId>US2008089901</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Immunogen HIVconsv</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A candidate HIV vaccine MVA.HIVA administered to 20-week-old infants in The Gambia
It is a prophylactic, not therapeutic vaccine</gtr:description><gtr:id>94AAA1DB-3AC0-4EC8-82B6-6A8BCEF42FC6</gtr:id><gtr:impact>The first MVA vectored HIV vaccine tested in African infants. the trial was mainly safety and capacity building</gtr:impact><gtr:outcomeId>jcYAjvbbqzP</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>PedVacc 001</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT00982579</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A candidate HIV vaccine MVA.HIVA delivered to 20-week old infants in Nairobi, Kenya born to HIV-infected mothers. The trial was mainly vaccine safety and capacity building.
It is a prophylactic, not therapeutic vaccine.</gtr:description><gtr:id>F384CD2A-D060-4698-A125-8BA452BA8FA5</gtr:id><gtr:impact>The first MVA-vectored candidate HIV vaccine administered to African infants; only the third HIV candidate infant vaccine trial in Africa</gtr:impact><gtr:outcomeId>CbjPoUtrve5</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>PedVacc 002</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT00981695</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Vaccine were manufactured for clinical trials in 2000</gtr:description><gtr:id>CEDDBCE7-EFD7-42C7-8154-6C64B7E37046</gtr:id><gtr:impact>First clinical assessment of candidate HIV-1 vaccines derived from an African HIV clade and tested in DNA-MVA regimen and a MVA.HIVA alone in infants</gtr:impact><gtr:outcomeId>F8734A67E46</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>pTH.HIVA and MVA.HIVA vaccines</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Vaccines targeting the conserved regions of HIV-1, therefore potentially controlling all clade in the target population and all escape mutants in infected individuals The HIVconsv immunogen is delivered by DNA, MVA, chimp adenovirus, Semiliki Forest virus replicons and synthetic long peptides</gtr:description><gtr:id>5313EE9D-DA73-49AA-A38A-9D09C5048552</gtr:id><gtr:impact>Tested in 7 clinical trials</gtr:impact><gtr:outcomeId>C2B0355D9AD</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Novel universal HIV-1 vaccines HIVconsv</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Two Infant HIV Vaccine Centres established, scientists are being trained, two clinical trials are under way</gtr:description><gtr:id>4C344906-8889-48FD-B43B-89DFA04FE21F</gtr:id><gtr:impact>Training and capacity building, safety and immunogenicity of a novel vaccine in infants</gtr:impact><gtr:outcomeId>0F99ABBFD6E</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Building capacity for infant HIV vaccine trials in two African sites</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5080D9C0-5FDE-4EA1-A11C-34850A848052</gtr:id><gtr:title>Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91a4a8d3630e6be3253b4d9100f94e3b"><gtr:id>91a4a8d3630e6be3253b4d9100f94e3b</gtr:id><gtr:otherNames>Abdul-Jawad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>56d184911c6ff0.22455449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>400AA86B-BAF7-4C1F-9192-91EDCBF46797</gtr:id><gtr:title>Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/943afd66240b87a716970ccd9ece4a71"><gtr:id>943afd66240b87a716970ccd9ece4a71</gtr:id><gtr:otherNames>Goonetilleke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>97240135F24</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36C48CA6-081B-443A-A152-AD7DEAB9C7D2</gtr:id><gtr:title>Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9f5ab962359496d9c21a8818ec01798"><gtr:id>b9f5ab962359496d9c21a8818ec01798</gtr:id><gtr:otherNames>Jaoko W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>1CF5330D69D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0AEC0BA-407F-4205-91D4-B5DC0853D43F</gtr:id><gtr:title>Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f2bc78d993328353b85908b6d3e4fcd"><gtr:id>4f2bc78d993328353b85908b6d3e4fcd</gtr:id><gtr:otherNames>Im EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>EC8CBB6FB80</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3AF3588-0566-41C0-9267-54A58D551E7F</gtr:id><gtr:title>Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f572a387945cca140ef638b2ec9ae59"><gtr:id>3f572a387945cca140ef638b2ec9ae59</gtr:id><gtr:otherNames>Roshorm Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>BA9F27ED5CA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40A09590-D29B-4BAA-ACE4-FE15F845BE1B</gtr:id><gtr:title>Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb3f8440bbc73f59706bbfe116514c10"><gtr:id>eb3f8440bbc73f59706bbfe116514c10</gtr:id><gtr:otherNames>Larke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>0FDA4550CE6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>371BD755-595A-4132-8099-23EAEE6C2C7E</gtr:id><gtr:title>Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b709ad3b8e7698295cad3772f08cf235"><gtr:id>b709ad3b8e7698295cad3772f08cf235</gtr:id><gtr:otherNames>Guimar?es-Walker A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>BCE44BE07D7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A80F7410-A35A-4FC0-BC21-04510A11F58F</gtr:id><gtr:title>Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Methods &amp; clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d6cfff7eac8005bf946988c16f2a92"><gtr:id>b6d6cfff7eac8005bf946988c16f2a92</gtr:id><gtr:otherNames>Saubi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2329-0501</gtr:issn><gtr:outcomeId>56d1890c5b6b50.35481587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE5C9784-B483-4083-BF30-72753675B02D</gtr:id><gtr:title>A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.</gtr:title><gtr:parentPublicationTitle>Journal of translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92e29644a267ffb27cceb67604bc0126"><gtr:id>92e29644a267ffb27cceb67604bc0126</gtr:id><gtr:otherNames>Mothe B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1479-5876</gtr:issn><gtr:outcomeId>56d18491d1e349.84440919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E651B36-CA5F-45F0-87CC-F0F5A71DFE75</gtr:id><gtr:title>A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd0b08c7569d3fbb892d3070c540098"><gtr:id>5bd0b08c7569d3fbb892d3070c540098</gtr:id><gtr:otherNames>Afolabi MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>dsdfuNP5kYF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A4BE3EA-6A85-4540-8E86-9916998A3DAC</gtr:id><gtr:title>On the growing complexity of HIV-1 vaccines</gtr:title><gtr:parentPublicationTitle>HIV Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>TX2G5maQW9T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>938D9F54-281C-4FFA-93B3-22A7612D2186</gtr:id><gtr:title>Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>doi_12588_014_885946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6084DDCB-070D-4360-9D3A-9C64D354B424</gtr:id><gtr:title>Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e7b5bfbb7d685aef71a3b09b947ac84"><gtr:id>0e7b5bfbb7d685aef71a3b09b947ac84</gtr:id><gtr:otherNames>Howles S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>oQa6GEMcu78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB7FC076-1E72-4EC9-8C4C-4DB52D913995</gtr:id><gtr:title>DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80ea5f2a56653c00efb611ec5b24e194"><gtr:id>80ea5f2a56653c00efb611ec5b24e194</gtr:id><gtr:otherNames>Koopman G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12588_28_24105029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>784FBC5F-AED1-4C52-9AB6-FF7EA94D4612</gtr:id><gtr:title>Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f2bc78d993328353b85908b6d3e4fcd"><gtr:id>4f2bc78d993328353b85908b6d3e4fcd</gtr:id><gtr:otherNames>Im EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>3A672CF13F5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7705667F-83F0-40FE-B5F1-CE36F4D233DC</gtr:id><gtr:title>Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41cb177d0a6d4515f8687dec3eaae05d"><gtr:id>41cb177d0a6d4515f8687dec3eaae05d</gtr:id><gtr:otherNames>Naarding MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>doi_12588_013_11_021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>653686EF-FEB1-4FB5-95B9-8869AD672F9D</gtr:id><gtr:title>On DNA vaccines and prolonged expression of immunogens.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>6422D319C2F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48A512B7-0F4C-4FEA-9AAD-2C6102440473</gtr:id><gtr:title>Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e491ba8e5b16c64ec3cb8b381ebef5a"><gtr:id>3e491ba8e5b16c64ec3cb8b381ebef5a</gtr:id><gtr:otherNames>Bridgeman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5CD4438B6D7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>221B64FD-4327-4070-B4F9-1598BE3D0D50</gtr:id><gtr:title>Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac96dbbd1f85203d1bf9e6ae89926a8d"><gtr:id>ac96dbbd1f85203d1bf9e6ae89926a8d</gtr:id><gtr:otherNames>Winstone N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5AE5BC0DF26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BE91929-F572-4CE0-9F66-D2D76CC264F6</gtr:id><gtr:title>STEP trial and HIV-1 vaccines inducing T-cell responses.</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>3989C7CEE29</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F5065DD-3C55-4206-8157-A40F52A103C7</gtr:id><gtr:title>Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.</gtr:title><gtr:parentPublicationTitle>Immunity, inflammation and disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1fb2f5be500cb027b90c8289746892c"><gtr:id>a1fb2f5be500cb027b90c8289746892c</gtr:id><gtr:otherNames>Borthwick NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2050-4527</gtr:issn><gtr:outcomeId>56d18491865047.68785172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>444612C7-FDA1-412F-AFCF-6C5A1CB043EA</gtr:id><gtr:title>Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d6cfff7eac8005bf946988c16f2a92"><gtr:id>b6d6cfff7eac8005bf946988c16f2a92</gtr:id><gtr:otherNames>Saubi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12588_28_22927933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8538938-A7FE-40E7-BD7D-C8A52AF24F9A</gtr:id><gtr:title>Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8af3eae12e9c3485ab2e2ff801c5b9f"><gtr:id>a8af3eae12e9c3485ab2e2ff801c5b9f</gtr:id><gtr:otherNames>Cebere I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>CC23AE8F745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB2C6F9D-E433-4D3A-8B80-89208D377887</gtr:id><gtr:title>Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/302ade6eef72f1f78249a8d74c749a76"><gtr:id>302ade6eef72f1f78249a8d74c749a76</gtr:id><gtr:otherNames>Borthwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_12588_28_24166483</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7709679C-0819-48CD-9E07-380DEA7C92B5</gtr:id><gtr:title>Infant Neutropenia Associated with Breastfeeding During Maternal Antiretroviral Treatment for Prevention of Mother-to-Child Transmission of HIV</gtr:title><gtr:parentPublicationTitle>Retrovirology: Research and Treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d298ff4ccafb616a9accbf8dc04f80e5"><gtr:id>d298ff4ccafb616a9accbf8dc04f80e5</gtr:id><gtr:otherNames>Njuguna</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56d18ac2b712c5.76253543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8E7C9FF-FF2E-4625-B103-80C4CB34CB86</gtr:id><gtr:title>A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16b26d8a504fa824577d7c9a7ea4c286"><gtr:id>16b26d8a504fa824577d7c9a7ea4c286</gtr:id><gtr:otherNames>Str?m P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>585d6721bc8a44.65792738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60C0A067-E3E2-4784-B547-7D892BC889F4</gtr:id><gtr:title>Developing HIV-1 vaccines with a positive attitude</gtr:title><gtr:parentPublicationTitle>Future HIV Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>43D6C62E988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DFF1E96-6BAE-41C0-82ED-080FD26B7778</gtr:id><gtr:title>Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0176ac52f7a3858de3221c9d5a7dfd0a"><gtr:id>0176ac52f7a3858de3221c9d5a7dfd0a</gtr:id><gtr:otherNames>Ondondo BO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>860B99B8CF9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0177D37-82A6-48F5-BD3E-3D08EA5055FE</gtr:id><gtr:title>Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>1273A829AA3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF9D5457-D481-4706-A1F2-9ABE6DACC1C7</gtr:id><gtr:title>Preclinical development of BCG.HIVA, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fc2a5e2b62a2df8a613fdb3b6454304"><gtr:id>5fc2a5e2b62a2df8a613fdb3b6454304</gtr:id><gtr:otherNames>Mahant A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>5a9d7e2b08e023.63055664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F64F5FE-0449-4123-9AC3-DF1A16DCD555</gtr:id><gtr:title>Transient IL-10 receptor blockade can enhance CD8(+) T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd46411c37ebf6a7f879374f9fe427a2"><gtr:id>fd46411c37ebf6a7f879374f9fe427a2</gtr:id><gtr:otherNames>Clutton G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>56d18492918879.87786301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F78C0332-C01D-4A53-8184-090222CA3BC0</gtr:id><gtr:title>Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02b9025275703fa69f602064c14a874"><gtr:id>f02b9025275703fa69f602064c14a874</gtr:id><gtr:otherNames>Ternette N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56d1849222eee9.59135668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EB0FD77-3998-4A54-B35D-2C5A253CEE1D</gtr:id><gtr:title>Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.</gtr:title><gtr:parentPublicationTitle>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b3f01879ba4030a8b294c146f44a632"><gtr:id>1b3f01879ba4030a8b294c146f44a632</gtr:id><gtr:otherNames>Vinner L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0903-4641</gtr:issn><gtr:outcomeId>A34E3F61A5F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24E520E8-7C44-4B6E-BB84-0E1CB561C967</gtr:id><gtr:title>Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>FDBFB683071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7611786-0172-4C90-B3A0-F18BB2EB30F1</gtr:id><gtr:title>Design and pre-clinical evaluation of a universal HIV-1 vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94b2f585dc4d4206ae8515f3b522e7d5"><gtr:id>94b2f585dc4d4206ae8515f3b522e7d5</gtr:id><gtr:otherNames>L?tourneau S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>93B809B22C4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ACCC1AF-53DE-4230-BEB0-F4A2AE2BE92B</gtr:id><gtr:title>Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_12588_28_23831324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEFBEF00-CE04-4475-B255-AE579FE1338B</gtr:id><gtr:title>Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/215a458258dd460674f9cc98e1c2b628"><gtr:id>215a458258dd460674f9cc98e1c2b628</gtr:id><gtr:otherNames>Hancock G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56d18492c3df64.59892738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5DE6799-BF36-437D-BB67-77CF07F38DC0</gtr:id><gtr:title>Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02b9025275703fa69f602064c14a874"><gtr:id>f02b9025275703fa69f602064c14a874</gtr:id><gtr:otherNames>Ternette N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>56d18491466883.85765963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41C376D0-071F-4DC7-8A68-CFC4DECFF1C9</gtr:id><gtr:title>Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0527f3251154b89261e24b442c909f60"><gtr:id>0527f3251154b89261e24b442c909f60</gtr:id><gtr:otherNames>Knudsen ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_12588_28_22318135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>364AEC07-AC22-44E1-9AE3-0F22A5D36A96</gtr:id><gtr:title>T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f572a387945cca140ef638b2ec9ae59"><gtr:id>3f572a387945cca140ef638b2ec9ae59</gtr:id><gtr:otherNames>Roshorm Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_12588_28_22930183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>220422C4-4568-40C7-93E9-FDC6DB8C208C</gtr:id><gtr:title>Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbfd9fb6e692d07596464ca94848bf67"><gtr:id>fbfd9fb6e692d07596464ca94848bf67</gtr:id><gtr:otherNames>Chen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5a9d7e2b6ca3b1.15375981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>793757C5-37DC-4FFF-8AEC-BA030971BC6F</gtr:id><gtr:title>Blocking development of a CD8+ T cell response by targeting lymphatic recruitment of APC.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c5a9c8be01312f74038c2cc7616212f"><gtr:id>0c5a9c8be01312f74038c2cc7616212f</gtr:id><gtr:otherNames>Teoh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>47091E418FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D4F6E39-D4AA-49E8-8A79-AFB53B2BD9F1</gtr:id><gtr:title>Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da746618b1b17a25497b2235af69178a"><gtr:id>da746618b1b17a25497b2235af69178a</gtr:id><gtr:otherNames>Dorrell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>FAC0B683CB3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8AB7939-1A7F-4C8D-90B1-7A15203AFB01</gtr:id><gtr:title>Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da746618b1b17a25497b2235af69178a"><gtr:id>da746618b1b17a25497b2235af69178a</gtr:id><gtr:otherNames>Dorrell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>84BC7C48F93</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF14C0EA-F29E-4982-A84C-86C325AADA13</gtr:id><gtr:title>Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f7291a65144b6159945ac5510fe4f1"><gtr:id>97f7291a65144b6159945ac5510fe4f1</gtr:id><gtr:otherNames>Ahmed T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56d181799398b1.94299235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>941755A7-184C-4C1F-9A6A-B4E143B9C138</gtr:id><gtr:title>Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/215a458258dd460674f9cc98e1c2b628"><gtr:id>215a458258dd460674f9cc98e1c2b628</gtr:id><gtr:otherNames>Hancock G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5a9d74bd940914.04465631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F76A5FA-B274-4D71-8438-A5FC51ABC37D</gtr:id><gtr:title>Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc978b730786aed29051550fd5070995"><gtr:id>cc978b730786aed29051550fd5070995</gtr:id><gtr:otherNames>Burgers WA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>42982A274F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFB0AD0B-9762-4180-9ED8-B6A4112E8933</gtr:id><gtr:title>Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4045ec99722c5d534bac690f76cfe482"><gtr:id>4045ec99722c5d534bac690f76cfe482</gtr:id><gtr:otherNames>Johnson LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>5a9d74bd06a026.47370927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DF7CB61-518A-4ACA-BA32-E6F893AC2829</gtr:id><gtr:title>Short communication: preclinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f2bc78d993328353b85908b6d3e4fcd"><gtr:id>4f2bc78d993328353b85908b6d3e4fcd</gtr:id><gtr:otherNames>Im EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>2C62E4D1114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAC6BF84-9F6C-4951-A7CF-454373DBE522</gtr:id><gtr:title>Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>8B55A793F75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDCE1885-0F07-4971-9B63-5BC99ED1F80F</gtr:id><gtr:title>A Novel T-cell Vaccine Eliciting T-cell Specificities Associated with Control of HIV-1 In Humans Is Highly Immunogenic in Mice and Macaques</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92e29644a267ffb27cceb67604bc0126"><gtr:id>92e29644a267ffb27cceb67604bc0126</gtr:id><gtr:otherNames>Mothe B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460aa11398035.30362313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B36B9866-0E71-4847-B095-8A405E3B7C7F</gtr:id><gtr:title>Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6e95ae915e653271600239431e5a2db"><gtr:id>b6e95ae915e653271600239431e5a2db</gtr:id><gtr:otherNames>Peters BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>B6F578C548D</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137884179</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>